Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CAMP

CAMP4 Therapeutics (CAMP) Stock Price, News & Analysis

CAMP4 Therapeutics logo

About CAMP4 Therapeutics Stock (NASDAQ:CAMP)

Advanced Chart

Key Stats

Today's Range
$3.52
$4.67
50-Day Range
$0.40
$4.00
52-Week Range
$1.31
$12.30
Volume
58,479 shs
Average Volume
99,265 shs
Market Capitalization
$29.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.50
Consensus Rating
Buy

Company Overview

CAMP4 Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

CAMP MarketRank™: 

CAMP4 Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 559th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CAMP4 Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    CAMP4 Therapeutics has received no research coverage in the past 90 days.

  • Read more about CAMP4 Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for CAMP4 Therapeutics are expected to grow in the coming year, from ($4.99) to ($2.89) per share.

  • Price to Book Value per Share Ratio

    CAMP4 Therapeutics has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for CAMP.
  • Dividend Yield

    CAMP4 Therapeutics does not currently pay a dividend.

  • Dividend Growth

    CAMP4 Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for CAMP.
  • Search Interest

    3 people have searched for CAMP on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CAMP4 Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    33.60% of the stock of CAMP4 Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about CAMP4 Therapeutics' insider trading history.
Receive CAMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CAMP4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CAMP Stock News Headlines

Washington prepares for war
While the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much bigger here at home. Emergency powers are being invoked, trillions are being mobilized, and the scale rivals anything we’ve seen since WWII. According to Porter Stansberry and Jeff Brown, a new economic arms race is already underway — one that could reshape markets, redirect capital, and impact billions of lives. They’ve just released an urgent briefing that explains what’s really happening behind the scenes, and which companies are positioned to benefit most.tc pixel
See More Headlines

CAMP Stock Analysis - Frequently Asked Questions

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) posted its earnings results on Thursday, August, 14th. The Wireless communications provider reported ($0.62) earnings per share for the quarter, beating analysts' consensus estimates of ($0.67) by $0.05. The Wireless communications provider earned $1.50 million during the quarter, compared to analysts' expectations of $0.73 million.

CAMP4 Therapeutics's stock reverse split on Friday, February 2nd 2024.The 1-23 reverse split was announced on Friday, February 2nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

CAMP4 Therapeutics subsidiaries include these companies: LoJack, Gulfstream Telematics, SmartLink Radio Networks, CalAmp Wireless Networks Inc., Skybility, Boisen S.A., CalAmp Importation and Leasing of Tracking Equipment Ltd., and others.

CAMP4 Therapeutics (CAMP) raised $75 million in an initial public offering (IPO) on Friday, October 11th 2024. The company issued 6,820,000 shares at $11.00 per share.

CAMP4 Therapeutics' top institutional shareholders include Geode Capital Management LLC (0.37%) and Bridgeway Capital Management LLC (0.12%). Insiders that own company stock include Polaris Management Co Vii, L, Jeffery R Gardner and Jason Cohenour.
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that CAMP4 Therapeutics investors own include Zimmer Biomet (ZBH), Union Pacific (UNP), Charter Communications (CHTR), NVIDIA (NVDA), PayPal (PYPL), MercadoLibre (MELI) and Meta Platforms (META).

Company Calendar

Last Earnings
8/14/2025
Today
9/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Communications Equipment
Current Symbol
NASDAQ:CAMP
CIK
730255
Employees
644
Year Founded
1981

Price Target and Rating

High Price Target
$23.00
Low Price Target
$8.00
Potential Upside/Downside
+1,030.1%
Consensus Rating
Buy
Rating Score (0-4)
3.17
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$51.79 million
Net Margins
N/A
Pretax Margin
-1,722.08%
Return on Equity
N/A
Return on Assets
-96.92%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.60
Quick Ratio
5.60

Sales & Book Value

Annual Sales
$650 thousand
Price / Sales
45.28
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.98 per share
Price / Book
0.74

Miscellaneous

Outstanding Shares
20,160,000
Free Float
13,387,000
Market Cap
$29.43 million
Optionable
No Data
Beta
N/A

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:CAMP) was last updated on 9/4/2025 by MarketBeat.com Staff
From Our Partners